Skip to main content Skip to main menu
UF Health University of Florida
Lamba Laboratory College of Pharmacy
Hiring Post-Doctoral Associate

Presentations

Selected Conference Presentations

64th Annual American Society of Hematology (ASH) Meeting and Exposition: December 10-13, 2022

* Indicates ASH Abstract Achievement Award

  1. Genome-Wide CRISPR/Cas9 Screen Identifies AraC-Daunorubicin-Etoposide (ADE) Response Modulators Associated with Clinical Outcomes in Pediatric AML

  2. Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10

  3. A Cibersortx Signature Predicts Outcome in Pediatric AML Patients*

  4. Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia*

  5. Proteomic Analysis Identifies Epigenetic Modifiers and Potential Negative Regulators of Leukemogenesis KMD6A and SETDB1 to be Induced Post In Vivo Decitabine Exposure in Pediatric AML

63rd Annual American Society of Hematology (ASH) Meeting and Exposition: December 11 – 14, 2021 

* Indicates ASH Abstract Achievement Award

  1. Pharmacogenomics of Fludarabine in Pediatric HCT Recipients: Preliminary Results *
  2. Unraveling Subcellular Localization of CD33 Splicing Polymorphism Variant
  3. The rs35112940 CD33 Polymorphism Reduces CD33 Internalization and Efficacy of CD33-Directed Gemtuzumab Ozogamicin
  4. Pharmacogenomics to Predict Mucositis in Acute Myeloid Leukemia
  5. Pharmacogenomic Single Nucleotide Polymorphism (SNP) Variants As Predictors of Toxicity Phenotypes in the Treatment of Acute Childhood Leukemia
  6. Impact of SAMHD1 Pharmacogenetics on Clinical Outcome in Pediatric AML *
  7. A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGx8) Score Predicts GO Response in AML *

American Society for Clinical Pharmacology & Therapeutics Annual Meeting: March 16 – 18, 2022

*Indicates Presidential Trainee Award; **Presidential Trainee Award and David J. Goldstein Trainee Award

  1. Pharmacogenomic Single Nucleotide Polymorphism (SNP) Scores as a Tool to Predict Toxicity Phenotypes in Treatment of Acute Childhood Leukemia (ALL) **
  2. A Polygenic DNA Damage Repair Pharmacogenomics (DDR_PGX) Score Predicts Response to Gemtuzumab Ozogamicin in Pediatric AML Patients *

American Association for Cancer Research (AACR) Annual Meeting: April 9 – 14, 2021

  1. Leukemic cell proteomic profiling in pediatric AML – Abstract No. 2535